US5296236A
(en)
*
|
1988-09-16 |
1994-03-22 |
Recordati S.A., Chemical And Pharmaceutical Company |
Controlled release therapeutic system for a liquid pharmaceutical formulations
|
ES2064564T3
(es)
*
|
1989-09-21 |
1995-02-01 |
American Cyanamid Co |
Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
|
US6764697B1
(en)
*
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
IT1252185B
(it)
*
|
1991-12-11 |
1995-06-05 |
Therapicon Srl |
Preparazioni farmaceutiche a liberazione programmata
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5681585A
(en)
*
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5472712A
(en)
*
|
1991-12-24 |
1995-12-05 |
Euroceltique, S.A. |
Controlled-release formulations coated with aqueous dispersions of ethylcellulose
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
EP0550108B1
(de)
*
|
1991-12-30 |
1998-03-18 |
Akzo Nobel N.V. |
Thyroaktive Zusammensetzung mit kontrollierter Freigabe
|
US7070806B2
(en)
*
|
1992-01-27 |
2006-07-04 |
Purdue Pharma Lp |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5262173A
(en)
*
|
1992-03-02 |
1993-11-16 |
American Cyanamid Company |
Pulsatile once-a-day delivery systems for minocycline
|
WO1993017673A1
(en)
*
|
1992-03-03 |
1993-09-16 |
Top Gold Pty., Limited |
Sustained release analgesics
|
JPH0733645A
(ja)
*
|
1992-05-28 |
1995-02-03 |
Elan Corp Plc |
錠剤製剤
|
CA2141435A1
(en)
*
|
1992-07-30 |
1994-02-17 |
William Byrne |
Ester of an organic nitrate and a salicylate
|
US5422122A
(en)
*
|
1992-08-04 |
1995-06-06 |
Eurand America, Incorporated |
Controlled release potassium chloride tablet
|
US5376384A
(en)
*
|
1992-12-23 |
1994-12-27 |
Kinaform Technology, Inc. |
Delayed, sustained-release pharmaceutical preparation
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
NZ260408A
(en)
|
1993-05-10 |
1996-05-28 |
Euro Celtique Sa |
Controlled release preparation comprising tramadol
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
WO1995003052A1
(en)
*
|
1993-07-22 |
1995-02-02 |
Warner-Lambert Company |
Controlled release tacrine drug delivery systems and methods for preparing same
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5662933A
(en)
*
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US6726930B1
(en)
|
1993-09-09 |
2004-04-27 |
Penwest Pharmaceuticals Co. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5773025A
(en)
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
US5484607A
(en)
*
|
1993-10-13 |
1996-01-16 |
Horacek; H. Joseph |
Extended release clonidine formulation
|
US5500227A
(en)
*
|
1993-11-23 |
1996-03-19 |
Euro-Celtique, S.A. |
Immediate release tablet cores of insoluble drugs having sustained-release coating
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US6210714B1
(en)
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
US5419917A
(en)
*
|
1994-02-14 |
1995-05-30 |
Andrx Pharmaceuticals, Inc. |
Controlled release hydrogel formulation
|
JP2716361B2
(ja)
*
|
1994-02-16 |
1998-02-18 |
株式会社アドバンス |
生体用プリント電極
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
US7060293B1
(en)
|
1994-05-25 |
2006-06-13 |
Purdue Pharma |
Powder-layered oral dosage forms
|
US6077533A
(en)
*
|
1994-05-25 |
2000-06-20 |
Purdue Pharma L.P. |
Powder-layered oral dosage forms
|
US5411745A
(en)
*
|
1994-05-25 |
1995-05-02 |
Euro-Celtique, S.A. |
Powder-layered morphine sulfate formulations
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5834024A
(en)
*
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
GB9503492D0
(en)
*
|
1995-02-22 |
1995-04-12 |
Ed Geistlich S Hne A G F R Che |
Chemical product
|
US20030109503A1
(en)
*
|
1995-06-06 |
2003-06-12 |
Smithkline Beecham P.L.C. |
Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
|
AU6122496A
(en)
*
|
1995-06-20 |
1997-01-22 |
Pharma-Vinci A/S |
A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
CZ293595B6
(cs)
*
|
1995-09-21 |
2004-06-16 |
Pharma Pass Llc |
Orální kompozice na bázi omeprazolu a způsob její přípravy
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US5837284A
(en)
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
US5773031A
(en)
*
|
1996-02-27 |
1998-06-30 |
L. Perrigo Company |
Acetaminophen sustained-release formulation
|
US20060068000A1
(en)
*
|
1996-03-25 |
2006-03-30 |
Wyeth |
Extended release formulation
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
AU695734B2
(en)
|
1996-07-08 |
1998-08-20 |
Penwest Pharmaceuticals Co. |
Sustained release matrix for high-dose insoluble drugs
|
IT1283478B1
(it)
*
|
1996-07-22 |
1998-04-21 |
Roberto Valducci |
Composizioni per integrazione nutrizionale comprendenti vitamine idrosolubili a rilascio prolungato
|
HRP970493A2
(en)
|
1996-09-23 |
1998-08-31 |
Wienman E. Phlips |
Oral delayed immediate release medical formulation and method for preparing the same
|
WO1998029095A2
(en)
*
|
1997-01-03 |
1998-07-09 |
Elan Corporation, Plc |
Sustained release cisapride mini-tablet formulation
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US5788987A
(en)
*
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
US20030124187A1
(en)
*
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
FR2760190B1
(fr)
*
|
1997-02-28 |
1999-04-09 |
Adir |
Composition pharmaceutique pour la liberation programmee de dexfenfluramine
|
US5840329A
(en)
*
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
AU8293498A
(en)
|
1997-07-02 |
1999-01-25 |
Euro-Celtique S.A. |
Stabilized sustained release tramadol formulations
|
MY125849A
(en)
*
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
US6056977A
(en)
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US6337091B1
(en)
|
1997-10-27 |
2002-01-08 |
Temple University - Of The Commonwealth System Of Higher Education |
Matrix for controlled delivery of highly soluble pharmaceutical agents
|
FR2774910B1
(fr)
*
|
1998-02-16 |
2001-09-07 |
Ethypharm Lab Prod Ethiques |
Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
|
UA65607C2
(uk)
*
|
1998-03-04 |
2004-04-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Фармацевтична композиція (варіанти) та спосіб її приготування
|
US6372254B1
(en)
|
1998-04-02 |
2002-04-16 |
Impax Pharmaceuticals Inc. |
Press coated, pulsatile drug delivery system suitable for oral administration
|
SI1077722T1
(sl)
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
US6197347B1
(en)
|
1998-06-29 |
2001-03-06 |
Andrx Pharmaceuticals, Inc. |
Oral dosage for the controlled release of analgesic
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6368625B1
(en)
|
1998-08-12 |
2002-04-09 |
Cima Labs Inc. |
Orally disintegrable tablet forming a viscous slurry
|
US6254891B1
(en)
*
|
1998-09-03 |
2001-07-03 |
Ascent Pediatrics, Inc. |
Extended release acetaminophen
|
US6126967A
(en)
*
|
1998-09-03 |
2000-10-03 |
Ascent Pediatrics |
Extended release acetaminophen particles
|
JP2000109341A
(ja)
|
1998-10-01 |
2000-04-18 |
Jsr Corp |
無機粒子含有組成物、転写フィルムおよびプラズマディスプレイパネルの製造方法
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
EP1125586A4
(de)
*
|
1998-10-26 |
2003-06-11 |
Tanabe Seiyaku Co |
Partikel mit verlängerter freisetzung
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
US20080118556A1
(en)
*
|
1998-11-02 |
2008-05-22 |
Elan Corporation, Plc |
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
|
US20090297597A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Gary Liversidge |
Modified Release Ticlopidine Compositions
|
NZ511442A
(en)
|
1998-11-02 |
2003-02-28 |
Elan Corp Plc |
Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US6270805B1
(en)
*
|
1998-11-06 |
2001-08-07 |
Andrx Pharmaceuticals, Inc. |
Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
|
EP2311441A1
(de)
|
1998-11-23 |
2011-04-20 |
Bonnie M. Davis |
Dosisformulierungen für Acetylcholinesterase-inhibitoren
|
US7083808B2
(en)
*
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6673367B1
(en)
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
PL349501A1
(en)
*
|
1998-12-24 |
2002-07-29 |
Janssen Pharmaceutica Nv |
Controlled release galantamine composition
|
ATE407949T1
(de)
|
1998-12-30 |
2008-09-15 |
Beth Israel Hospital |
Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
|
US6274162B1
(en)
|
2000-01-14 |
2001-08-14 |
Bpsi Holdings, Inc. |
Elegant film coating system
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6294199B1
(en)
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US7250176B1
(en)
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US6410255B1
(en)
*
|
1999-05-05 |
2002-06-25 |
Aurora Biosciences Corporation |
Optical probes and assays
|
KR20060110013A
(ko)
|
1999-05-14 |
2006-10-23 |
니리어스 파마슈티컬즈, 인크. |
신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들, 상기조절인자들의 합성 및 상기 조절인자들의 사용 방법
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
FR2794646B1
(fr)
|
1999-06-09 |
2001-09-21 |
Ethypharm Lab Prod Ethiques |
Microgranules de sulfate de morphine, procede de preparation et composition les contenant
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
DE60044904D1
(de)
|
1999-09-03 |
2010-10-14 |
Brigham & Womens Hospital |
Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
|
ES2168043B1
(es)
*
|
1999-09-13 |
2003-04-01 |
Esteve Labor Dr |
Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
|
JP2003509439A
(ja)
*
|
1999-09-14 |
2003-03-11 |
スミスクライン・ビーチャム・コーポレイション |
水性コーティングされたビーズレットの製法
|
ATE391495T1
(de)
*
|
1999-09-30 |
2008-04-15 |
Penwest Pharmaceuticals Co |
Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
|
EP2295043A1
(de)
|
1999-10-29 |
2011-03-16 |
Euro-Celtique S.A. |
Hydrocodon-Formulierungen mit gesteuerter Freisetzung
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
JP2003523769A
(ja)
|
2000-02-23 |
2003-08-12 |
ヴァーテックス ファーマシューティカルズ (サンディエゴ)エルエルシー |
改変された蛍光タンパク質
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US7025989B2
(en)
*
|
2000-02-24 |
2006-04-11 |
Advancis Pharmaceutical Corp. |
Multiple-delayed released antibiotic product, use and formulation thereof
|
US6627222B2
(en)
|
2000-02-24 |
2003-09-30 |
Advancis Pharmaceutical Corp. |
Amoxicillin-dicloxacillin antibiotic composition
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6663890B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Metronidazole antibiotic product, use and formulation thereof
|
US6638532B2
(en)
|
2000-02-24 |
2003-10-28 |
Advancis Pharmaceutical Corp. |
Tetracycline—doxycycline antibiotic composition
|
US6730320B2
(en)
|
2000-02-24 |
2004-05-04 |
Advancis Pharmaceutical Corp. |
Tetracycline antibiotic product, use and formulation thereof
|
US6667042B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Fluroquinilone antibiotic product, use and formulation thereof
|
US6667057B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Levofloxacin antibiotic product, use and formulation thereof
|
EP1267765A4
(de)
*
|
2000-02-24 |
2008-12-24 |
Middlebrook Pharmaceuticals In |
Antibiotische und pilzbekämpfende mittel
|
US6610328B2
(en)
|
2000-02-24 |
2003-08-26 |
Advancis Pharmaceutical Corp. |
Amoxicillin-clarithromycin antibiotic composition
|
US6991807B2
(en)
*
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
US6669948B2
(en)
|
2000-02-24 |
2003-12-30 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6663891B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Erythromyacin antibiotic product, use and formulation thereof
|
US6623758B2
(en)
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Cephalosporin-metronidazole antibiotic composition
|
US6632453B2
(en)
|
2000-02-24 |
2003-10-14 |
Advancis Pharmaceutical Corp. |
Ciprofoxacin-metronidazole antibiotic composition
|
US20030060487A1
(en)
*
|
2000-04-12 |
2003-03-27 |
Bamdad R. Shoshana |
Treatment of neurodegenerative disease
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
SI1296714T1
(sl)
|
2000-06-22 |
2010-01-29 |
S For Entpr University Of Iowa |
Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
|
DE10033023A1
(de)
*
|
2000-07-07 |
2002-01-31 |
Biogrund Gmbh |
Filmüberzugszusammensetzung auf Basis von Zellulosederivaten und Zuckeralkoholen
|
US6855721B1
(en)
|
2000-07-28 |
2005-02-15 |
Indevus Pharmaceuticals, Inc. |
Methods and compositions for alleviating stuttering
|
DE60110814D1
(de)
*
|
2000-08-10 |
2005-06-16 |
Jds Pharmaceuticals Llc |
Zusammensetzungen mit langsamer freigabe enthaltend lithium-carbonat
|
WO2002030392A2
(en)
|
2000-10-12 |
2002-04-18 |
Beecham Pharmaceuticals (Pte) Limited |
Formulation containing amoxicillin
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
US7105174B2
(en)
*
|
2000-10-13 |
2006-09-12 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-neoplastic product, use and formulation thereof
|
US7157095B2
(en)
*
|
2000-10-13 |
2007-01-02 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release antifungal product, use and formulation thereof
|
US7074417B2
(en)
*
|
2000-10-13 |
2006-07-11 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-viral product, use and formulation thereof
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US6344215B1
(en)
|
2000-10-27 |
2002-02-05 |
Eurand America, Inc. |
Methylphenidate modified release formulations
|
KR101167465B1
(ko)
|
2000-10-30 |
2012-07-27 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
WO2002047610A2
(en)
*
|
2000-11-16 |
2002-06-20 |
The Regents Of The University Of California |
Marine actinomycete taxon for drug and fermentation product dicovery
|
WO2002056022A2
(en)
|
2000-11-27 |
2002-07-18 |
Minerva Biotechnologies Corp |
Diagnostics, drug screening and treatment for cancer
|
WO2002069369A2
(en)
|
2000-12-08 |
2002-09-06 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
US6706274B2
(en)
*
|
2001-01-18 |
2004-03-16 |
Scimed Life Systems, Inc. |
Differential delivery of nitric oxide
|
ITMI20010220A1
(it)
*
|
2001-02-05 |
2002-08-05 |
Valpharma Sa |
Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
|
US20020197314A1
(en)
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
ES2436523T3
(es)
*
|
2001-03-13 |
2014-01-02 |
Endo Pharmaceuticals Inc. |
Formas de dosificación terapéutica
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20030070584A1
(en)
|
2001-05-15 |
2003-04-17 |
Cynthia Gulian |
Dip coating compositions containing cellulose ethers
|
ATE446751T1
(de)
|
2001-06-05 |
2009-11-15 |
Univ Chicago |
Verwendung von methylnaltrexon zur behandlung von immunsuppression
|
ES2314099T3
(es)
|
2001-08-17 |
2009-03-16 |
Coley Pharmaceutical Gmbh |
Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
|
US8309118B2
(en)
|
2001-09-28 |
2012-11-13 |
Mcneil-Ppc, Inc. |
Film forming compositions containing sucralose
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
WO2003030656A2
(en)
|
2001-10-06 |
2003-04-17 |
Merial Limited |
Methods and compositions for promoting growth and innate immunity in young animals
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
US6780437B2
(en)
*
|
2001-10-23 |
2004-08-24 |
Upsher-Smith Laboratories, Inc. |
Coated potassium chloride granules and tablets
|
WO2003039595A2
(en)
*
|
2001-11-07 |
2003-05-15 |
Inex Pharmaceuticals Corporation |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
US6821532B2
(en)
*
|
2001-11-16 |
2004-11-23 |
Unitel Technologies, Inc. |
Methods and compositions for the treatment of benign prostatic hypertrophy
|
US6663888B2
(en)
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
KR20030056474A
(ko)
*
|
2001-12-28 |
2003-07-04 |
한국유나이티드제약 주식회사 |
카르비도파/레보도파 서방정의 조성물과 그의 제조방법
|
US20030190343A1
(en)
*
|
2002-03-05 |
2003-10-09 |
Pfizer Inc. |
Palatable pharmaceutical compositions for companion animals
|
US7022342B2
(en)
*
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
ES2734652T3
(es)
|
2002-04-04 |
2019-12-11 |
Zoetis Belgium S A |
Oligorribonucleótidos inmunoestimulantes que contienen G y U
|
IL164221A0
(en)
*
|
2002-04-09 |
2005-12-18 |
Flamel Tech Sa |
Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
|
AU2003246792B2
(en)
|
2002-04-09 |
2008-08-28 |
Flamel Ireland Limited |
Oral suspension of active principle microcapsules
|
US6958161B2
(en)
*
|
2002-04-12 |
2005-10-25 |
F H Faulding & Co Limited |
Modified release coated drug preparation
|
US7125563B2
(en)
*
|
2002-04-12 |
2006-10-24 |
Dava Pharmaceuticals, Inc. |
Sustained release pharmaceutical preparations and methods for producing the same
|
ATE407665T1
(de)
|
2002-05-06 |
2008-09-15 |
Massachusetts Inst Technology |
Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
|
CA2484897C
(en)
|
2002-05-09 |
2015-10-06 |
The Brigham And Women's Hospital, Inc. |
Soluble st2 as a cardiovascular disease marker and therapeutic target
|
US20040009943A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Pathogen vaccines and methods for using the same
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
NZ537628A
(en)
*
|
2002-06-26 |
2005-12-23 |
Alza Corp |
Minimally compliant, volume efficient piston for osmotic drug delivery systems
|
BRPI0312331A2
(pt)
*
|
2002-07-03 |
2016-06-28 |
Pericor Science Inc |
composições de ácido hialurônico e métodos de emprego.
|
US20050226926A1
(en)
|
2002-07-25 |
2005-10-13 |
Pfizer Inc |
Sustained-release tablet composition of pramipexole
|
PE20040134A1
(es)
*
|
2002-07-25 |
2004-03-06 |
Pharmacia Corp |
Forma de dosificacion de una vez al dia de pramipexol
|
US7429619B2
(en)
|
2002-08-02 |
2008-09-30 |
Mcneil Consumer Healthcare |
Polyacrylic film forming compositions
|
US7985422B2
(en)
*
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
US7160913B2
(en)
*
|
2002-09-13 |
2007-01-09 |
Thomas Jefferson University |
Methods and kit for treating Parkinson's disease
|
US20050020613A1
(en)
*
|
2002-09-20 |
2005-01-27 |
Alpharma, Inc. |
Sustained release opioid formulations and method of use
|
US7112581B2
(en)
*
|
2002-09-27 |
2006-09-26 |
Nereus Pharmaceuticals, Inc. |
Macrocyclic lactams
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
US20030049698A1
(en)
*
|
2002-10-08 |
2003-03-13 |
Wang Timothy C. |
Diagnosis and treatment of gastrointestinal disease
|
TWI319713B
(en)
*
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
SI2241325T1
(sl)
|
2002-10-29 |
2012-05-31 |
Coley Pharm Group Inc |
Uporaba CPG oligonukleotidov pri zdravljenju okužbe z virusom hepatitisa C
|
EP2363410B1
(de)
|
2002-11-27 |
2017-10-11 |
Minerva Biotechnologies Corporation |
MUC1-Isoformen
|
US9107804B2
(en)
*
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
WO2004052374A1
(en)
*
|
2002-12-12 |
2004-06-24 |
Altana Pharma Ag |
Combination medicament
|
US20040114368A1
(en)
*
|
2002-12-13 |
2004-06-17 |
Shyu Shing Jy |
Light device having rotatable or movable view
|
CL2003002653A1
(es)
*
|
2002-12-18 |
2005-04-22 |
Wyeth Corp |
Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
|
AU2003301121A1
(en)
*
|
2002-12-18 |
2004-07-14 |
Pain Therapeutics, Inc. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
US20040253311A1
(en)
*
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US20070218139A1
(en)
*
|
2002-12-20 |
2007-09-20 |
Smith Thomas J |
High Pressure Compaction For Pharmaceutical Formulations
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
DK2325302T3
(en)
|
2003-02-11 |
2016-03-14 |
Shire Human Genetic Therapies |
Cells expressing a sulfatase and a C-formylglycine-generating enzyme and methods and uses thereof
|
EP1599474B1
(de)
*
|
2003-03-04 |
2013-04-24 |
California Institute Of Technology |
Heterocyclische oligomere Verbindungen zur DNS-Erkennung
|
DE10311585A1
(de)
*
|
2003-03-14 |
2004-09-23 |
Basf Ag |
Wirkstoffhaltige Adsorbate
|
US20050152967A1
(en)
*
|
2003-03-28 |
2005-07-14 |
Pfab, Lp |
Dynamic variable release
|
DK2368553T3
(en)
|
2003-04-08 |
2015-02-09 |
Progenics Pharm Inc |
Pharmaceutical preparation comprising methylnaltrexone
|
ITMI20030827A1
(it)
*
|
2003-04-18 |
2004-10-19 |
Unihart Corp |
Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
|
US20040241252A1
(en)
*
|
2003-05-29 |
2004-12-02 |
Abney Christopher Charles |
Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
|
CA2534816A1
(en)
|
2003-06-12 |
2004-12-23 |
Evan Newell |
Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
|
JP2007523862A
(ja)
*
|
2003-06-20 |
2007-08-23 |
ネレアス ファーマシューティカルズ インコーポレイテッド |
癌、炎症及び感染性疾患の治療のための、[3.2.0]複素環式化合物およびそれらの類縁体の使用
|
ZA200600473B
(en)
*
|
2003-06-20 |
2007-04-25 |
Univ California |
Salinosporamides and methods for use thereof
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
US7632521B2
(en)
*
|
2003-07-15 |
2009-12-15 |
Eurand, Inc. |
Controlled release potassium chloride tablets
|
CA2533358C
(en)
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
US8313775B2
(en)
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
CA2533178C
(en)
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
CA2445420A1
(en)
|
2003-07-29 |
2005-01-29 |
Invitrogen Corporation |
Kinase and phosphatase assays
|
US7619059B2
(en)
|
2003-07-29 |
2009-11-17 |
Life Technologies Corporation |
Bimolecular optical probes
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
CA2535177A1
(en)
|
2003-08-11 |
2005-02-24 |
Advancis Pharmaceutical Corporation |
Robust pellet
|
US8062672B2
(en)
|
2003-08-12 |
2011-11-22 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
WO2005016317A1
(en)
*
|
2003-08-19 |
2005-02-24 |
Themis Laboratories Private Limited |
Process for manufacture of extended release pellets containing diltiazem hci
|
US20060173171A1
(en)
*
|
2003-08-26 |
2006-08-03 |
Bamdad Cynthia C |
Techniques and compositions for diagnosis and treatment of cancer (muci)
|
AU2004270170B2
(en)
*
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US8460710B2
(en)
|
2003-09-15 |
2013-06-11 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
AU2004271744B2
(en)
*
|
2003-09-16 |
2010-07-29 |
Covis Pharma B.V. |
Use of ciclesonide for the treatment of respiratory diseases
|
EP1670442A4
(de)
*
|
2003-09-19 |
2011-09-14 |
Penwest Pharmaceuticals Co |
Dosierformen mit verzögerter freisetzung
|
JP2007519608A
(ja)
*
|
2003-09-19 |
2007-07-19 |
ペンウェスト ファーマシューティカルズ カンパニー |
時間治療用剤形
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
AU2004280143A1
(en)
*
|
2003-10-11 |
2005-04-21 |
Tekmira Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
US20050095299A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Wynn David W. |
Controlled release analgesic suspensions
|
US20050095288A1
(en)
*
|
2003-11-03 |
2005-05-05 |
Andrx Labs, Llc |
Decongestant and expectorant tablets
|
US20070292498A1
(en)
*
|
2003-11-05 |
2007-12-20 |
Warren Hall |
Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
|
EP1686976A2
(de)
*
|
2003-11-05 |
2006-08-09 |
Santarus, Inc. |
Kombination aus protonenpumpenhemmer und schlafmittel
|
US7387793B2
(en)
*
|
2003-11-14 |
2008-06-17 |
Eurand, Inc. |
Modified release dosage forms of skeletal muscle relaxants
|
US20050143350A1
(en)
*
|
2003-11-19 |
2005-06-30 |
Seed John C. |
Combination drug therapy to treat obesity
|
WO2005060610A2
(en)
*
|
2003-12-11 |
2005-07-07 |
The Trustees Of Columbia University In The City Ofnew York |
Nano-sized particles, processes of making, compositions and uses thereof
|
US20050232986A1
(en)
*
|
2003-12-17 |
2005-10-20 |
David Brown |
Dosage form containing promethazine and another drug
|
US20050266032A1
(en)
*
|
2003-12-17 |
2005-12-01 |
Sovereign Pharmaceuticals, Ltd. |
Dosage form containing multiple drugs
|
US9492541B2
(en)
*
|
2004-09-14 |
2016-11-15 |
Sovereign Pharmaceuticals, Llc |
Phenylepherine containing dosage form
|
US20050281875A1
(en)
*
|
2003-12-17 |
2005-12-22 |
Sovereign Pharmaceuticals, Ltd. |
Promethazine containing dosage form
|
EP2248895B8
(de)
|
2003-12-19 |
2016-09-21 |
Autotelic LLC |
Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
|
US7452730B2
(en)
*
|
2004-01-16 |
2008-11-18 |
California Institute Of Technology |
DNA-binding polymers
|
EP1711486B1
(de)
*
|
2004-01-23 |
2011-05-11 |
Nereus Pharmaceuticals, Inc. |
Als antimikrobielle mittel geeignete bisindolpyrrole
|
EP1568383A3
(de)
|
2004-02-27 |
2005-11-16 |
Antisense Pharma GmbH |
Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
|
US20070185067A1
(en)
*
|
2004-02-27 |
2007-08-09 |
Altana Pharma Ag |
Ciclesonide and glycopyrronium combination
|
US20070155685A1
(en)
*
|
2004-02-27 |
2007-07-05 |
Karl-Hermann Schlingensiepen |
Pharmaceutical composition
|
US20050226927A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
US20050220873A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Chien-Hsuan Han |
Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
|
WO2005102366A2
(en)
*
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Lithium combinations, and uses related thereto
|
JP2007533706A
(ja)
*
|
2004-04-20 |
2007-11-22 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
|
AU2005236068C1
(en)
|
2004-04-21 |
2012-08-30 |
Beth Israel Deaconess Medical Center, Inc. |
Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
CA2564731A1
(en)
|
2004-04-27 |
2005-11-10 |
Medicinova, Inc. |
Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
|
US7579371B2
(en)
|
2004-04-30 |
2009-08-25 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
RU2382637C2
(ru)
*
|
2004-04-30 |
2010-02-27 |
Астеллас Фарма Инк. |
Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
|
EP2025679A3
(de)
*
|
2004-04-30 |
2009-07-08 |
Nereus Pharmaceuticals, Inc. |
[3,2,0]-Heterocyclische Verbindungen und Verfahren zu Ihrer Verwendung
|
US7691874B2
(en)
*
|
2004-05-14 |
2010-04-06 |
Hyoung-Chun KIM |
Neuroprotective properties of dextrorotatory morphinans
|
MX339690B
(es)
*
|
2004-06-04 |
2016-06-06 |
Xenoport Inc |
Profarmacos de levodopa y sus composiciones y usos.
|
US7323585B2
(en)
*
|
2004-06-04 |
2008-01-29 |
Xenoport, Inc. |
Levodopa prodrugs, and compositions and uses thereof
|
JP5563735B2
(ja)
|
2004-06-16 |
2014-07-30 |
タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド |
Ppi多回剤形
|
US9308164B2
(en)
|
2004-06-30 |
2016-04-12 |
Sovereign Pharmaceuticals, Llc |
Hyoscyamine dosage form
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US8715727B2
(en)
|
2004-07-02 |
2014-05-06 |
Shionogi Inc. |
Tablet for pulsed delivery
|
US9592197B2
(en)
*
|
2004-12-16 |
2017-03-14 |
Sovereign Pharmaceuticals, Llc |
Dosage form containing diphenhydramine and another drug
|
US20070003622A1
(en)
*
|
2004-12-16 |
2007-01-04 |
Sovereign Pharmaceuticals, Ltd. |
Diphenhydramine containing dosage form
|
CA2576386A1
(en)
*
|
2004-08-13 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
|
JP4757872B2
(ja)
*
|
2004-08-13 |
2011-08-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
|
US10624858B2
(en)
*
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EP2338993B1
(de)
|
2004-09-02 |
2013-06-12 |
Yale University |
Regulierung von Onkogenen durch mikro-RNAs
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
WO2007053135A1
(en)
*
|
2004-09-14 |
2007-05-10 |
Minerva Biotechnologies Corporation |
Methods for diagnosis and treatment of cancer
|
US20060062811A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Szymczak Christopher E |
Medicinal cooling emulsions
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
EP1802285B1
(de)
|
2004-10-21 |
2013-02-27 |
Aptalis Pharmatech, Inc. |
Geschmacksverdeckende pharmazeutische zusammensetzungen mit magenlöslichen porenbildnern
|
AU2005304687B2
(en)
|
2004-11-11 |
2012-01-19 |
The General Hosptial Corporation |
Parathyroid hormone receptor activation and stem and progenitor cell expansion
|
WO2006060676A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Dana Farber Cancer Institute |
Compositions and methods for treating neoplastic diseases
|
WO2006063078A2
(en)
*
|
2004-12-08 |
2006-06-15 |
Elan Corporation, Plc |
Topiramate pharmaceuticals composition
|
US20060127421A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Celgene Corporation |
Treatment using D-threo methylphenidate
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
US8299025B2
(en)
|
2005-02-03 |
2012-10-30 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
US20090123536A1
(en)
*
|
2005-02-21 |
2009-05-14 |
Flamel Technologies, S.A. |
Oral Pharmaceutical Form of Losartan
|
FR2882259A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US9662390B2
(en)
*
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
ES2720288T3
(es)
|
2005-03-30 |
2019-07-19 |
Minerva Biotechnologies Corp |
Proliferación de células que expresan MUC1
|
EP2527365A3
(de)
|
2005-03-30 |
2013-02-20 |
Minerva Biotechnologies Corporation |
Proliferation von MUC1-ausdrückenden Zellen
|
EA200702221A1
(ru)
*
|
2005-04-12 |
2008-04-28 |
Элан Фарма Интернэшнл Лимитед |
Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
|
WO2006113792A2
(en)
|
2005-04-19 |
2006-10-26 |
Eli Lilly And Company |
Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
|
CA2609788A1
(en)
*
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
US9161918B2
(en)
*
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
BRPI0611452A2
(pt)
|
2005-05-05 |
2010-09-08 |
Antisense Pharma Gmbh |
dosagem de oligonucleotìdeos
|
US20060257473A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Porranee Puranajoti |
Extended release tablet
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
WO2007037790A2
(en)
*
|
2005-06-08 |
2007-04-05 |
Elan Corporation, Plc |
Modified release famciclovir compositions
|
PT2163562E
(pt)
|
2005-06-21 |
2013-12-19 |
Xoma Us Llc |
Anticorpos de ligação a il 1 beta e respectivos fragmentos
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
US20070003621A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
US7893299B2
(en)
|
2005-07-21 |
2011-02-22 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
EP1957093B1
(de)
|
2005-08-29 |
2017-04-12 |
SHASHOUA, Victor E. |
Neuroprotektive und neurorestorative verfahren und zusammensetzungen
|
WO2007048220A2
(en)
*
|
2005-09-09 |
2007-05-03 |
Labopharm Inc. |
Trazodone composition for once a day adminisitiation
|
US20070098796A1
(en)
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
|
US20070098791A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
|
US8658608B2
(en)
*
|
2005-11-23 |
2014-02-25 |
Yale University |
Modified triple-helix forming oligonucleotides for targeted mutagenesis
|
EP1957647B1
(de)
|
2005-11-25 |
2015-03-04 |
Zoetis Belgium S.A. |
Immunstimulierende oligoribonukleotide
|
ES2812250T3
(es)
*
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
US7563821B2
(en)
*
|
2005-12-05 |
2009-07-21 |
Xenoport, Inc. |
Levodopa prodrug mesylate, compositions thereof, and uses thereof
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
WO2007090881A2
(en)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Modified release formulation
|
US20090098202A1
(en)
*
|
2006-02-10 |
2009-04-16 |
Boehringer Ingelheim International Gmbh |
Extended Release Formulation
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
EP2007360B1
(de)
|
2006-04-03 |
2014-11-26 |
Isa Odidi |
Abgabevorrichtung mit organosol-beschichtung und kontrollierter freisetzung
|
WO2007120638A2
(en)
*
|
2006-04-12 |
2007-10-25 |
President And Fellows Of Harvard College |
Methods and compositions for modulating glycosylation
|
US20070253927A1
(en)
*
|
2006-04-13 |
2007-11-01 |
Gwenaelle Jegou |
Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
|
AU2007247480B8
(en)
*
|
2006-04-28 |
2013-04-11 |
Grunenthal Gmbh |
Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
WO2007140191A2
(en)
|
2006-05-23 |
2007-12-06 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
KR101106510B1
(ko)
|
2006-05-30 |
2012-01-20 |
인타르시아 세라퓨틱스 인코포레이티드 |
투피스, 내부채널 삼투압 전달 시스템 유동 조절기
|
PE20080151A1
(es)
*
|
2006-06-01 |
2008-02-25 |
Schering Plough Healthcare |
Formulaciones farmaceuticas de fenilefrina y composiciones para su absorcion en el colon
|
NZ573174A
(en)
*
|
2006-06-01 |
2012-01-12 |
Msd Consumer Care Inc |
Sustained release pharmaceutical dosage form containing phenylephrine
|
EP2029105A1
(de)
*
|
2006-06-01 |
2009-03-04 |
Schering Corporation |
Phenylphrinformulierungen mit gepulster freisetzung und pharmazeutische zusammensetzungen damit
|
CN101505735A
(zh)
*
|
2006-06-01 |
2009-08-12 |
先灵公司 |
用于持续释放去氧肾上腺素的药用组合物
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
US8748419B2
(en)
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
US7893053B2
(en)
|
2006-06-16 |
2011-02-22 |
Theracos, Inc. |
Treating psychological conditions using muscarinic receptor M1 antagonists
|
KR101141333B1
(ko)
|
2006-06-20 |
2012-05-23 |
트랜스진 에스.에이. |
재조합 바이러스 백신
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
US20080057122A1
(en)
*
|
2006-08-31 |
2008-03-06 |
Aaipharma Inc. |
Acetaminophen pharmaceutical compositions
|
WO2008027557A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Spherics, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
WO2008147426A2
(en)
*
|
2006-10-04 |
2008-12-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for immunomodulation
|
EP2813144A1
(de)
*
|
2006-10-09 |
2014-12-17 |
Charleston Laboratories, Inc. |
Analgetische Zusammensetzungen enthaltend ein Antihistamin
|
US7645616B2
(en)
*
|
2006-10-20 |
2010-01-12 |
The University Of Hong Kong |
Use of lipocalin-2 as a diagnostic marker and therapeutic target
|
US20090297626A1
(en)
*
|
2006-11-03 |
2009-12-03 |
The Trustees Of Columbia University In The City Of New York |
Methods for preparing metal oxides
|
CA2618240C
(en)
|
2006-11-17 |
2015-01-20 |
Supernus Pharmaceuticals, Inc. |
Sustained-release formulations of topiramate
|
US8394415B2
(en)
*
|
2006-11-21 |
2013-03-12 |
Mcneil-Ppc, Inc |
Modified release analgesic suspensions
|
CA2670636A1
(en)
|
2006-11-27 |
2008-06-05 |
H. Lundbeck A/S |
Heteroaryl amide derivatives
|
WO2008066899A2
(en)
*
|
2006-11-28 |
2008-06-05 |
Marinus Pharmaceuticals |
Nanoparticulate formulations and methods for the making and use thereof
|
RU2554747C9
(ru)
|
2006-12-20 |
2015-10-20 |
Ксома (Сша) Ллс |
Способы лечения il-1бета-зависимых заболеваний
|
TW200843731A
(en)
*
|
2006-12-21 |
2008-11-16 |
Xenoport Inc |
Catechol protected levodopa diester prodrugs, compositions, and methods of use
|
JP2011502953A
(ja)
*
|
2006-12-21 |
2011-01-27 |
ゼノポート,インコーポレーテッド |
ジメチル置換されたレボドパジエステルのプロドラッグ、組成物及び使用方法
|
WO2008079868A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Drugtech Corporation |
Clonidine composition and method of use
|
EP2063867A2
(de)
*
|
2006-12-22 |
2009-06-03 |
Combinatorx, Incorporated |
Pharmazeutische zusammensetzungen zur behandlung von morbus parkinson und damit verbundenen leiden
|
EP2099911A2
(de)
*
|
2007-01-11 |
2009-09-16 |
Yale University |
Zusammensetzungen und verfahren zur gezielten deaktivierung von hiv-zelloberflächen-rezeptoren
|
WO2008094877A2
(en)
*
|
2007-01-30 |
2008-08-07 |
Drugtech Corporation |
Compositions for oral delivery of pharmaceuticals
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
US7824698B2
(en)
*
|
2007-02-02 |
2010-11-02 |
Nereus Pharmaceuticals, Inc. |
Lyophilized formulations of Salinosporamide A
|
US8679541B2
(en)
|
2007-03-14 |
2014-03-25 |
Particle Dynamics International, Llc |
Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
|
US20100111943A1
(en)
*
|
2007-03-22 |
2010-05-06 |
Medical College Of Georgia Research Institute, Inc |
Compositions and methods for inhibiting cancer metastasis
|
CA2682129A1
(en)
|
2007-03-29 |
2008-10-09 |
Progenics Pharmaceuticals, Inc. |
Crystal forms and uses thereof
|
ES2493590T3
(es)
|
2007-03-29 |
2014-09-12 |
Wyeth Llc |
Antagonistas de receptores opioides periféricos y usos de los mismos
|
WO2008121348A2
(en)
|
2007-03-29 |
2008-10-09 |
Progenics Pharmaceuticals, Inc. |
Peripheral opioid receptor antagonists and uses thereof
|
CA2682202C
(en)
|
2007-04-02 |
2016-01-12 |
Theracos, Inc. |
Benzylic glycoside derivatives and methods of use
|
CN103316326B
(zh)
|
2007-04-04 |
2016-06-15 |
希格默伊德药业有限公司 |
环孢菌素药物组合物
|
PT2644205T
(pt)
|
2007-04-12 |
2018-10-19 |
Brigham & Womens Hospital Inc |
Direcionamento a abcb5 para tratamento oncológico
|
WO2008130619A2
(en)
*
|
2007-04-20 |
2008-10-30 |
Trustees Of Boston College |
A composition comprising an inhibitor of pde4 and/or pde7
|
US8951570B2
(en)
|
2007-04-26 |
2015-02-10 |
Sigmoid Pharma Limited |
Manufacture of multiple minicapsules
|
WO2008137747A1
(en)
|
2007-05-02 |
2008-11-13 |
The Regents Of The University Of Michigan |
Nanoemulsion therapeutic compositions and methods of using the same
|
AU2008252577A1
(en)
*
|
2007-05-17 |
2008-11-27 |
Coley Pharmaceutical Gmbh |
Class A oligonucleotides with immunostimulatory potency
|
CN101848706A
(zh)
*
|
2007-06-01 |
2010-09-29 |
先灵-普劳健康护理产品公司 |
包含底物和含活性成分和聚乙烯醇的包衣的药用组合物
|
CA2689978A1
(en)
*
|
2007-06-08 |
2008-12-18 |
Addrenex Pharmaceuticals, Inc. |
Extended release formulation and method of treating adrenergic dysregulation
|
CN101784263B
(zh)
*
|
2007-06-08 |
2012-11-07 |
贝林格尔.英格海姆国际有限公司 |
奈韦拉平的延长释放制剂
|
US20100172991A1
(en)
*
|
2007-06-08 |
2010-07-08 |
Henry Joseph Horacek |
Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
|
US9833510B2
(en)
*
|
2007-06-12 |
2017-12-05 |
Johnson & Johnson Consumer Inc. |
Modified release solid or semi-solid dosage forms
|
WO2008156676A1
(en)
*
|
2007-06-15 |
2008-12-24 |
President And Fellows Of Harvard College |
Methods and compositions for detecting and modulating o-glycosylation
|
WO2009002456A2
(en)
*
|
2007-06-21 |
2008-12-31 |
Massachusetts Institute Of Technology |
Methods and compositions relating to progenitor cells
|
US20090017167A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Herbalife International Inc. |
Mixture and beverage made therefrom for protecting cellular hydration
|
EP2591787A1
(de)
|
2007-08-13 |
2013-05-15 |
Pfizer Inc |
Kombinations-motif-immunstimulierende Oligonukleotide mit verbesserter Wirkung
|
KR101107425B1
(ko)
|
2007-08-23 |
2012-01-19 |
테라코스, 인코포레이티드 |
벤질벤젠 유도체 및 사용 방법
|
KR20170097787A
(ko)
|
2007-10-12 |
2017-08-28 |
다케다 파마슈티칼스 유에스에이, 인코포레이티드 |
음식 섭취와 관계없이 위장 장애를 치료하는 방법
|
JP5453280B2
(ja)
*
|
2007-10-16 |
2014-03-26 |
ラボファーム インコーポレイテッド |
アセトアミノフェンおよびトラマドールを持続的に放出するための二層組成物
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
PE20091084A1
(es)
*
|
2007-12-07 |
2009-07-23 |
Schering Plough Healthcare |
Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
|
CA2707980C
(en)
|
2007-12-17 |
2015-05-12 |
Labopharm Inc. |
Misuse preventative, controlled release formulation
|
AU2008343085B2
(en)
|
2007-12-20 |
2015-03-12 |
Xoma (Us) Llc |
Methods for the treatment of gout
|
US20090202633A1
(en)
*
|
2008-01-03 |
2009-08-13 |
Siva Ramakrishna Velaga |
Extended release formulations of guaifenesin
|
CA2749273C
(en)
|
2008-01-09 |
2018-09-04 |
Charleston Laboratories, Inc. |
Pharmaceutical oral dosage form comprising a triptan and an antiemetic
|
CA2713568C
(en)
|
2008-02-06 |
2016-09-20 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
EP2257626A2
(de)
*
|
2008-03-01 |
2010-12-08 |
Abraxis BioScience, LLC |
Behandlung, diagnostikum und verfahren zur entdeckung eines antagonisten unter verwendung sparc-spezifischer mirnas
|
EP2278966B1
(de)
|
2008-03-21 |
2019-10-09 |
The University of Chicago |
Behandlung mit opioid-antagonisten und mtor-inhibitoren
|
EP2385370A1
(de)
|
2008-04-10 |
2011-11-09 |
Massachusetts Institute of Technology (MIT) |
Verfahren zur Erkennung und Verwendung von auf Krebsstammzellen abzielenden Mitteln
|
US20100227853A1
(en)
*
|
2008-04-18 |
2010-09-09 |
Trustees Of Boston College |
Inhibitors of cyclic amp phosphodiesterases
|
CA2722589A1
(en)
|
2008-04-25 |
2009-10-29 |
Innate Pharma |
Improved tlr3 agonist compositions
|
CA2723716A1
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by mirna
|
US8524772B2
(en)
*
|
2008-05-09 |
2013-09-03 |
Tiara Pharmaceuticals, Inc. |
Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation
|
BRPI0912234A2
(pt)
*
|
2008-05-12 |
2015-10-06 |
Nereus Pharmaceuticals Inc |
derivados de salinosporamida como inibidores de proteassomas
|
WO2009151561A2
(en)
|
2008-06-12 |
2009-12-17 |
President And Fellows Of Harvard College |
Methods and compounds for antimicrobial intervention
|
BRPI0916769A2
(pt)
|
2008-07-15 |
2017-09-26 |
Theracos Inc |
derivados de benzilbenzeno deuterados e métodos de uso
|
WO2010011347A2
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
BRPI0917444A2
(pt)
|
2008-08-15 |
2015-12-01 |
Depomed Inc |
composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
|
EP2324002B1
(de)
|
2008-08-22 |
2016-10-05 |
Theracos Sub, LLC |
Verfahren zur herstellung von sglt2-hemmern
|
US20110092493A1
(en)
*
|
2008-09-24 |
2011-04-21 |
Clark Levi |
Dose-controlled transdermal promethazine compositions and methods of use
|
JP5722782B2
(ja)
*
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
CA2738414C
(en)
*
|
2008-09-29 |
2014-05-27 |
Wockhardt Research Centre |
Extended release dosage form of ropinirole
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
KR20170110740A
(ko)
|
2008-10-09 |
2017-10-11 |
미네르바 바이오테크놀로지 코포레이션 |
세포내에서 다능성을 유도하기 위한 방법
|
US8399513B2
(en)
*
|
2008-10-20 |
2013-03-19 |
Xenoport, Inc. |
Levodopa prodrug mesylate hydrate
|
WO2010047775A2
(en)
*
|
2008-10-20 |
2010-04-29 |
Xenoport, Inc. |
Methods of synthesizing a levodopa ester prodrug
|
EP3130923B1
(de)
|
2008-11-14 |
2020-02-12 |
The Brigham and Women's Hospital, Inc. |
Therapeutische verfahren im zusammenhang mit krebsstammzellen
|
EP2376089B1
(de)
|
2008-11-17 |
2018-03-14 |
The Regents of the University of Michigan |
Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür
|
PT2358360T
(pt)
|
2008-11-18 |
2016-11-15 |
Ucb Biopharma Sprl |
Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
|
WO2010068483A2
(en)
|
2008-11-25 |
2010-06-17 |
University Of Rochester |
Mlk inhibitors and methods of use
|
US8486449B2
(en)
|
2008-12-16 |
2013-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
EP2403539A2
(de)
|
2009-03-02 |
2012-01-11 |
Massachusetts Institute of Technology |
Verfahren und systeme zur behandlung und/oder diagnose
|
US8309356B2
(en)
*
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
EP2424363A1
(de)
*
|
2009-05-01 |
2012-03-07 |
Atley Pharmaceuticals, Inc. |
Zusammensetzungen mit einem antihistaminikum, hustenlindernden und abschwellenden mittel mit retard-formulierung
|
JP2012525424A
(ja)
*
|
2009-05-01 |
2012-10-22 |
アトリー ファーマシューティカルズ インコーポレイテッド |
抗ヒスタミン剤と鎮咳剤と充血緩和剤とを徐放性製剤中に含む組成物
|
WO2010130374A1
(en)
|
2009-05-14 |
2010-11-18 |
Bayer Animal Health Gmbh |
Enhanced immune response in avian species
|
WO2010133609A2
(en)
|
2009-05-18 |
2010-11-25 |
Sigmoid Pharma Limited |
Composition comprising oil drops
|
JP2012528858A
(ja)
|
2009-06-01 |
2012-11-15 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
O−GlcNAc転移酵素阻害剤およびその使用
|
EP3020412B1
(de)
|
2009-06-16 |
2017-10-11 |
The Regents of the University of Michigan |
Nanoemulsionsimpfstoffe
|
EP3311667A1
(de)
|
2009-07-08 |
2018-04-25 |
Charleston Laboratories, Inc. |
Pharmazeutische zusammensetzungen
|
EP2456432B1
(de)
|
2009-07-22 |
2024-02-28 |
University of Massachusetts |
Zusammensetzungen zur verringerung von oxidativem stress
|
AU2010277554B2
(en)
|
2009-07-30 |
2015-02-19 |
Antisense Pharma Gmbh |
Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
|
GB2485327A
(en)
|
2009-08-12 |
2012-05-09 |
Sigmoid Pharma Ltd |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
EP2287304A1
(de)
|
2009-08-17 |
2011-02-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Neuartige Behandlung von Patienten nach Stentimplantation oder Ballondilatation und neuartige Arzneimittel eluierende Stents
|
RU2016108987A
(ru)
|
2009-08-18 |
2018-11-26 |
Вентиркс Фармасьютикалз, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
|
PT2467377T
(pt)
|
2009-08-18 |
2017-04-04 |
Array Biopharma Inc |
Benzoazepinas substituídas como moduladores de recetores de tipo toll
|
HUE035862T2
(en)
|
2009-09-28 |
2018-05-28 |
Intarcia Therapeutics Inc |
Rapid development and / or completion of substantially steady-state drug delivery
|
NZ601747A
(en)
|
2009-11-09 |
2014-08-29 |
Xenoport Inc |
Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
|
AU2010325746B2
(en)
|
2009-12-02 |
2016-02-25 |
Adare Pharmaceuticals S.R.L. |
Fexofenadine microcapsules and compositions containing them
|
WO2011133803A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
US20110293585A1
(en)
|
2010-04-21 |
2011-12-01 |
Helix Therapeutics, Inc. |
Compositions and methods for treatment of lysosomal storage disorders
|
EP3138915A1
(de)
|
2010-05-04 |
2017-03-08 |
The Brigham and Women's Hospital, Inc. |
Erkennung und behandlung von fibrose
|
JP2013526523A
(ja)
|
2010-05-11 |
2013-06-24 |
シマ ラブス インク. |
メトプロロールを含むアルコール耐性持続放出性経口剤形
|
US8846909B2
(en)
|
2010-05-24 |
2014-09-30 |
University Of Rochester |
Bicyclic heteroaryl kinase inhibitors and methods of use
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
ES2722204T3
(es)
|
2010-12-22 |
2019-08-08 |
Bayer Ip Gmbh |
Respuesta inmune mejorada en especies bovinas
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
HUE032036T2
(en)
|
2011-01-12 |
2017-08-28 |
Ventirx Pharmaceuticals Inc |
Toll-type receptor modulator substituted benzodiazepines
|
ES2620605T3
(es)
|
2011-01-12 |
2017-06-29 |
Ventirx Pharmaceuticals, Inc. |
Benzoazepinas sustituidas como moduladores de receptores tipo Toll
|
US9222085B2
(en)
|
2011-02-03 |
2015-12-29 |
Mirna Therapeutics, Inc. |
Synthetic mimics of MIR-124
|
JP2014506791A
(ja)
|
2011-02-03 |
2014-03-20 |
マーナ セラピューティクス インコーポレイテッド |
miR−34の合成模倣体
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
EP3502236B1
(de)
|
2011-02-18 |
2023-08-23 |
The Scripps Research Institute |
Gezielte differenzierung von oligodendrozyten-vorläuferzellen zu einem myelinierungszellenschicksal
|
AU2012245198B2
(en)
|
2011-04-21 |
2017-07-13 |
Trustees Of Tufts College |
Compositions and methods for stabilization of active agents
|
AU2012262014B2
(en)
|
2011-06-01 |
2016-07-14 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
WO2012167053A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
US8524664B2
(en)
|
2011-06-02 |
2013-09-03 |
Colorado Seminary, Which owns and Operates The Univeristy of Denver |
Methods of treating overproduction of cortisol using ACTH antagonist peptides
|
US8759313B2
(en)
|
2011-08-03 |
2014-06-24 |
The Charlotte-Mecklenburg Hospital Authority |
Treatment of fibrosis using microRNA 19b
|
SG10201608671SA
(en)
|
2011-07-18 |
2016-12-29 |
Harvard College |
Engineered Microbe-Targeting Molecules and Uses Thereof
|
WO2013013061A1
(en)
|
2011-07-19 |
2013-01-24 |
University Of Vermont And State Agricultural College |
Methods and compounds for treating cancer
|
EP2763677B1
(de)
|
2011-10-04 |
2020-02-26 |
Janus Biotherapeutics, Inc. |
Neue immunsystemmodulatoren auf imidazolchinolin-basis
|
US9173884B2
(en)
|
2011-11-30 |
2015-11-03 |
Trustees Of Boston College |
Inhibitors of phosphodiesterase 11 (PDE11)
|
US8962687B2
(en)
|
2012-12-05 |
2015-02-24 |
Medicinova, Inc. |
Method of treating liver disorders
|
US8835499B2
(en)
|
2011-12-08 |
2014-09-16 |
Medicinova, Inc. |
Method of treating non-alcoholic fatty liver disease and steatohepatitis
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
US10583169B2
(en)
|
2012-07-11 |
2020-03-10 |
University Of Vermont And State Agricultural College |
Methylation-controlled J protein (MCJ) for treatment of liver disease and altering mitochondrial metabolism
|
JP6246121B2
(ja)
|
2012-07-13 |
2017-12-13 |
株式会社新日本科学 |
キラル核酸アジュバント
|
US8962020B2
(en)
*
|
2012-07-26 |
2015-02-24 |
Glycadia Inc. |
Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
|
US9636376B2
(en)
*
|
2012-09-11 |
2017-05-02 |
Innopharma, Inc. |
Stable compositions of peptide epoxy ketones
|
EP3795694A3
(de)
|
2012-10-02 |
2021-06-23 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Verfahren für mit dem dna-erfassungspfad assoziierten leiden
|
WO2014055941A2
(en)
|
2012-10-04 |
2014-04-10 |
Pappalardo Juan Sabastian |
Compounds and methods for targeted immune system delivery
|
WO2014074805A1
(en)
|
2012-11-08 |
2014-05-15 |
Whitehead Institute For Biomedical Research |
Selective targeting of cancer stem cells
|
WO2014085795A1
(en)
|
2012-11-30 |
2014-06-05 |
University Of Rochester |
Mixed lineage kinase inhibitors for hiv/aids therapies
|
EP2931272A1
(de)
|
2012-12-12 |
2015-10-21 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Verfahren zur behandlung von leberfibrose und assoziierte erkrankungen durch regulierung der rev-erb-aktivität
|
US9872851B2
(en)
|
2012-12-12 |
2018-01-23 |
The Charlotte-Mecklenburg Hospital Authority |
Methods of treating portal hypertension
|
EP3412682B1
(de)
|
2013-03-15 |
2022-08-31 |
Trustees Of Tufts College |
Niedermolekulare seidenzusammensetzungen und stabilisierende seidenzusammensetzungen
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
US9987233B2
(en)
|
2013-03-21 |
2018-06-05 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
US20150031769A1
(en)
|
2013-07-25 |
2015-01-29 |
Medicinova, Inc. |
Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
|
US10286078B2
(en)
|
2013-09-13 |
2019-05-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
US20150238631A1
(en)
|
2013-10-15 |
2015-08-27 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
CA2927543C
(en)
|
2013-10-15 |
2021-07-20 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
US10208102B2
(en)
|
2013-11-01 |
2019-02-19 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
US11452767B2
(en)
|
2013-11-15 |
2022-09-27 |
Oslo Universitetssykehus Hf |
CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
US10513546B2
(en)
|
2013-12-18 |
2019-12-24 |
President And Fellows Of Harvard College |
CRP capture/detection of gram positive bacteria
|
KR20160101073A
(ko)
|
2013-12-20 |
2016-08-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
US10149905B2
(en)
|
2014-01-15 |
2018-12-11 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
BR112016019837A2
(pt)
|
2014-02-28 |
2017-10-17 |
Bayer Animal Health Gmbh |
plasmídeos imunoestimuladores
|
US10398672B2
(en)
|
2014-04-29 |
2019-09-03 |
Whitehead Institute For Biomedical Research |
Methods and compositions for targeting cancer stem cells
|
WO2015170195A1
(en)
*
|
2014-05-03 |
2015-11-12 |
GORREPATI, Navaneeta Krishna |
Hydrazaline hydrochloride pellets and its preparation method
|
US9346754B2
(en)
|
2014-05-08 |
2016-05-24 |
Medicinova, Inc. |
Method of treating advanced non-alcoholic steatohepatitis
|
US20150321989A1
(en)
|
2014-05-08 |
2015-11-12 |
Medicinova, Inc. |
Method of treating idiopathic pulmonary fibrosis
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
EP3140269B1
(de)
|
2014-05-09 |
2023-11-29 |
Yale University |
Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
|
EP3148523B1
(de)
|
2014-06-02 |
2023-08-16 |
MediciNova, Inc. |
Verfahren zur hemmung der behandlung von fibrose
|
EP3183251A4
(de)
|
2014-08-22 |
2017-12-27 |
Janus Biotherapeutics, Inc. |
Neuartige n2,n4,n7,6-tetrasubstituerte pteridin-2,4,7-triamin- und 2,4,6,7-ted pteridin-verbindungen und verfahren zur synthese und verwendung davon
|
AU2015312134A1
(en)
|
2014-09-02 |
2017-03-23 |
Bhupinder Singh |
Deuterated or a non-deuterated molecule and pharmaceutical formulations
|
HUE054957T2
(hu)
*
|
2014-09-15 |
2021-10-28 |
Orphazyme As |
Arimoklomol készítése
|
US9795571B2
(en)
|
2014-09-19 |
2017-10-24 |
The Procter & Gamble Company |
Pulsed release phenylephrine dosage forms
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
WO2016057563A1
(en)
|
2014-10-08 |
2016-04-14 |
Pacific Northwest Diabetes Research Institute |
Methods and compositions for increasing the potency of antifungal agents
|
ES2924988T3
(es)
|
2014-10-10 |
2022-10-13 |
Univ Michigan Regents |
Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
|
EP3206491B1
(de)
|
2014-10-17 |
2019-11-27 |
Salix Pharmaceuticals, Inc. |
Verwendung von methylnaltrexon zur verringerung der tumorprogression
|
CA2936741C
(en)
|
2014-10-31 |
2018-11-06 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
CA2966801A1
(en)
|
2014-11-07 |
2016-05-12 |
Sigmoid Pharma Limited |
Compositions comprising cyclosporin
|
AU2015346037A1
(en)
|
2014-11-14 |
2017-07-06 |
Gemphire Therapeutics Inc. |
Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers
|
JP6827924B2
(ja)
|
2014-11-26 |
2021-02-10 |
メディシノバ・インコーポレイテッドMediciNova, Inc. |
イブジラスト及びリルゾールの組み合わせを含む医薬および組成物
|
MA41152A
(fr)
*
|
2014-12-12 |
2017-10-17 |
Johnson & Johnson Consumer Inc |
Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
|
EP3234193B1
(de)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molekulare biomarker für krebsimmuntherapie
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
EP3256494A4
(de)
|
2015-02-10 |
2018-12-05 |
Minerva Biotechnologies Corporation |
Humanisierte anti-muc1*-antikörper
|
JP6944373B2
(ja)
|
2015-02-18 |
2021-10-06 |
ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジUniversity Of Vermont And State Agricultural College |
Mcjアゴニストおよびそれらに関する使用
|
EP3268034A4
(de)
|
2015-03-05 |
2018-11-14 |
Northwestern University |
Nichtneuroinvasive viren und verwendungen davon
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
EP3283113A4
(de)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimierte pne-basierte chimäre t-zell-rezeptor-schalter und verwendungen davon
|
ES2794628T3
(es)
|
2015-04-15 |
2020-11-18 |
Univ Massachusetts |
Composiciones y métodos para la reactivación de cromosomas XI
|
CN116196401A
(zh)
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
EP3302354B1
(de)
|
2015-06-03 |
2023-10-04 |
i2o Therapeutics, Inc. |
Systeme zum einsetzen eines implantats
|
EP3310376A4
(de)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
Modifizierte therapeutische mittel und zusammensetzungen daraus
|
AU2016293834A1
(en)
|
2015-07-10 |
2018-02-01 |
Asociación Centro de Investigación Cooperativa en Biociencias- CIC bioGUNE |
MCJ inhibitors for use in treating drug-induced diseases and conditions
|
WO2017024114A1
(en)
|
2015-08-06 |
2017-02-09 |
President And Fellows Of Harvard College |
Improved microbe-binding molecules and uses thereof
|
ES2876930T3
(es)
|
2015-08-20 |
2021-11-15 |
Asociacion Centro De Investig Cooperativa En Biociencias Cic Biogune |
Métodos y composiciones para tratar enfermedades y afecciones hepáticas
|
AU2016324144B2
(en)
|
2015-09-17 |
2021-07-29 |
University Of Massachusetts |
Compositions and methods for modulating FMR1 expression
|
EP3364955B1
(de)
|
2015-10-09 |
2022-04-20 |
RB Health (US) LLC |
Pharmazeutische formulierung
|
US11351124B2
(en)
|
2015-10-27 |
2022-06-07 |
Eupraxia Pharmaceuticals Inc. |
Sustained release of formulations of local anesthetics
|
CN108348491A
(zh)
*
|
2015-11-06 |
2018-07-31 |
燿石治疗公司 |
治疗混合性血脂异常
|
EP3416976A2
(de)
|
2016-02-16 |
2018-12-26 |
Yale University |
Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
|
US20200308590A1
(en)
|
2016-02-16 |
2020-10-01 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
CA3013795A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Corr-Jensen Inc. |
Time release vitamins and minerals in edible oils
|
EP3423041A4
(de)
|
2016-03-04 |
2019-09-11 |
Charleston Laboratories, Inc. |
Pharmazeutische zusammensetzungen
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
EP3439692A4
(de)
|
2016-04-08 |
2020-01-22 |
ITI Health, Inc. |
Plectin-1-antikörper und verwendungen davon
|
BR112018073511A2
(pt)
|
2016-05-16 |
2019-03-26 |
Intarcia Therapeutics, Inc. |
polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
|
WO2017207623A1
(en)
|
2016-05-31 |
2017-12-07 |
Université de Lausanne |
Mirna as biomarkers and regulators of cancer stem cells
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
US20190322643A1
(en)
|
2016-06-29 |
2019-10-24 |
Georgia State University Research Foundation, Inc. |
Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
|
CA3030105A1
(en)
*
|
2016-07-17 |
2018-01-25 |
Mapi Pharma Ltd. |
Extended release dosage forms of pregabalin
|
CN109689095B
(zh)
|
2016-07-26 |
2023-10-03 |
拜耳动物保健有限责任公司 |
牛物种中增加的生育力
|
US20180042903A1
(en)
|
2016-08-11 |
2018-02-15 |
Ovid Therapeutics Inc. |
Methods and compositions for treatment of epileptic disorders
|
US20190201350A1
(en)
*
|
2016-08-15 |
2019-07-04 |
Corr-Jensen Inc. |
Time release of fat-soluble actives
|
KR102613430B1
(ko)
|
2016-10-19 |
2023-12-18 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
WO2018085842A1
(en)
|
2016-11-07 |
2018-05-11 |
University Of Massachusetts |
Therapeutic targets for facioscapulohumeral muscular dystrophy
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
EP3574116A1
(de)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
|
WO2018145109A1
(en)
|
2017-02-06 |
2018-08-09 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
US10278930B2
(en)
|
2017-03-16 |
2019-05-07 |
The Procter & Gamble Company |
Method for relieving sinus congestion
|
US20200113821A1
(en)
|
2017-04-04 |
2020-04-16 |
Yale University |
Compositions and methods for in utero delivery
|
US11225512B2
(en)
|
2017-04-27 |
2022-01-18 |
University Of New Hampshire |
Compositions and methods for ceramide-elevating therapeutic strategies
|
EP3651750A4
(de)
|
2017-07-14 |
2021-04-14 |
University of Massachusetts |
Verfahren und zusammensetzungen zur behandlung von entzündungen
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
US20210069319A1
(en)
|
2017-09-07 |
2021-03-11 |
University Of Oslo |
Vaccine molecules
|
WO2019154884A1
(en)
|
2018-02-07 |
2019-08-15 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for determining cancer invasiveness and patient prognosis
|
EP3773612A4
(de)
|
2018-03-28 |
2022-01-12 |
Herbalife International of America, Inc. |
Acetylierung von polysacchariden
|
PL3773537T3
(pl)
|
2018-04-19 |
2022-05-23 |
Tvardi Therapeutics, Inc. |
Inhibitory stat3
|
US20210340562A1
(en)
|
2018-10-19 |
2021-11-04 |
Board Of Regents, The University Of Texas System |
Engineered long interspersed element (line) transposons and methods of use
|
US20210393592A1
(en)
*
|
2018-11-02 |
2021-12-23 |
Celltrion Inc. |
Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
MX2021005967A
(es)
|
2018-11-21 |
2021-10-13 |
Tremeau Pharmaceuticals Inc |
Formas purificadas de rofecoxib, métodos de fabricación y uso.
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
EP3677693A1
(de)
|
2019-01-03 |
2020-07-08 |
Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO |
Transpochimäre gentranskripte (tcgts) als krebsbiomarker
|
US20220175934A1
(en)
|
2019-03-21 |
2022-06-09 |
Mitotherapeutix Llc |
Multivalent ligand clusters for targeted delivery of therapeutic agents
|
WO2020257776A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
|
US20220372474A1
(en)
|
2019-06-21 |
2022-11-24 |
Yale University |
Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
|
US20220280656A1
(en)
|
2019-07-31 |
2022-09-08 |
Yale University |
Compositions and methods for treating sickle cell disease
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
AU2020371784A1
(en)
|
2019-10-24 |
2022-06-02 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
US10945992B1
(en)
|
2019-11-13 |
2021-03-16 |
Tremeau Pharmaceuticals, Inc. |
Dosage forms of rofecoxib and related methods
|
MX2022006014A
(es)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
|
WO2021168373A1
(en)
|
2020-02-21 |
2021-08-26 |
Mitotherapeutix Llc |
Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|
US11071739B1
(en)
|
2020-09-29 |
2021-07-27 |
Genus Lifesciences Inc. |
Oral liquid compositions including chlorpromazine
|
EP4059498A1
(de)
|
2021-03-16 |
2022-09-21 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Verfahren und zusammensetzungen zur behandlung von zuständen im zusammenhang mit hypermineralisierung
|
US11161833B1
(en)
|
2021-04-09 |
2021-11-02 |
Tremeau Pharmaceuticals, Inc. |
Deuterated etoricoxib, methods of manufacture, and use thereof
|
AU2022264339A1
(en)
|
2021-04-28 |
2023-11-09 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
WO2022237974A1
(en)
|
2021-05-12 |
2022-11-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Krab-containing zinc finger protein and cancer
|
CA3217719A1
(en)
|
2021-05-28 |
2022-12-01 |
Kazuko Matsuda |
Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels
|
EP4352226A1
(de)
|
2021-06-07 |
2024-04-17 |
Yale University |
Peptidnukleinsäuren zur räumlich-zeitlichen steuerung der crispr-cas-bindung
|
WO2024039376A1
(en)
|
2022-08-18 |
2024-02-22 |
Elanco Us Inc. |
Method for improving growth performance in feedlot cattle
|